Genitourinary (GU) Cancer
Roche is leading the investigation of new options for patients suffering from genitourinary cancer, exploring the potential of cancer immunotherapy and treatment tailored to individuals.
IMvigor130: a phase III study of atezolizumab with or without platinum-based chemotherapy in previously untreated metastatic urothelial carcinoma
This presentation reports the primary efficacy and safety data for the Phase 3 IMvigor130 trial investigating ▼atezolizumab with or without chemotherapy versus placebo with chemotherapy in patients with metastatic urothelial cancer who have not been previously treated. With a median follow-up of 11.8 months, final PFS, interim OS, ORR, DOR, and safety results will be shown.
Dr. Grande discusses IMvigor130: a phase III study of atezolizumab with or without platinum-based chemotherapy in previously untreated metastatic urothelial carcinoma
In this video, Dr. Grande discusses the Phase 3 IMvigor130 trial investigating atezolizumab with or without chemotherapy versus placebo with chemotherapy in patients with metastatic urothelial cancer who have not been previously treated. He reviews the study design, final PFS, interim OS, ORR, DOR, safety results, as well as the study results in comparison to the current treatment landscape.
Safety and efficacy of ▼atezolizumab in patients with autoimmune disease: subgroup analysis of the SAUL study in locally advanced/metastatic urinary tract carcinoma
In prespecified analyses of the subgroup of 35 patients with pre-existing autoimmune disease (AID) treated with ▼atezolizumab for urinary tract carcinoma in the single-arm Phase IIIb SAUL study, incidences of adverse events (AEs) of special interest and treatment-related AEs appeared acceptable. Efficacy in patients with AID seemed at least similar to efficacy in non-AID patients. Treating patients with AID requires caution but AID is not a barrier to ▼atezolizumab therapy per se.
ASCO GU 2019
Long-term outcomes in elderly patients (pts) from IMvigor210: atezolizumab (atezo) in metastatic urothelial cancer (mUC)
This poster presents results from a post-hoc analysis investigating the efficacy and safety of atezolizumab monotherapy in IMvigor210 patients with mUC ≥ 65 and ≥ 75 years. In this post hoc analysis, ORR, DOR, OS and safety were evaluated in subgroups based on age and PD-L1 status.
Treatment (Tx) characteristics of patients (pts) with locally advanced or metastatic urothelial cancer (mUC) receiving atezolizumab (atezo) monotherapy in US clinical practice
This poster presents the first analysis of atezolizumab monotherapy use in patients with mUC treated in routine clinical practice in the US. 1L and 2L+ treatment data from the Flatiron Health EHR-derived database were compared with data from the IMvigor210 and IMvigor211 clinical trials. Time on treatment, distribution of treatment cycles and patient characteristics by treatment are reported.
Bladder Cancer: The Facts
Bladder cancer is one of several cancers associated with a high rate of mutations, which may be linked to a heightened immunogenicity. Learn more about the role of tumour-infiltrating immune cells and the pathways governing the immune response.